Cardio

Circulatory support specialist Thoratec Corporation, has acquired the DuraHeart® II ventricular assist system from Terumo Corporation for an upfront cash payment of $13 million. Together with potential future milestone payments this could end up at $43.5 million.

C. R. Bard, Inc. has entered into an agreement to sell certain assets of its Electrophysiology division to Boston Scientific Corporation for $275 million in cash. The transaction is expected to close in 2013, subject to certain regulatory and customary closing conditions.

St. Jude Medical, Inc. has gained regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and launch of the Accent MRI™ Pacemaker and the Tendril MRI™ lead.

For the first time in the UK, the RhinoChill® IntraNasal Cooling System is being jointly evaluated by an ambulance service … continue reading “First UK Evaluation of Continuous Targeted Brain Cooling In Cardiac Arrest From Street To ITU”

The U.S. FDA has cleared for marketing Rhythmlink’s Disposable MR Conditional Cup Electrodes, the first of a kind to be formally authorized for use.

Boston Scientific Corporation is launching a new family of pacemakers in Europe, which monitor respiration, adjust pacing accordingly, and support insight into the patient’s overall heart failure status.

CardioFocus, Inc., has announced that its HeartLight® technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.

Boston Scientific Corporation is trumpeting a poster presentation at this week’s EHRA EuroPace 2013 in Athens. Data suggests the company’s … continue reading “Poster Points To Lower Complications For Boston’s S-ICD® System Vs Transvenous ICD Leads”

Pacing and remote monitoring technology company Biotronik has announced the European market launch of its Ilesto 7 Series. Ilesto 7 … continue reading “EU Market Sees Launch Of World’s First MR Approved DF4 ICD/CRT-D System”

Edwards Lifesciences Corporation, is trumpeting the news that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the Edwards SAPIEN XT valve, making it the country’s first commercially available transcatheter aortic heart valve.

St.Jude Medical, Inc. has received CE Mark approval of its next-generation quadripolar device, the Quadra Assura MP™ cardiac resynchronization therapy defibrillator.

A study of the Carpentier-Edwards PERIMOUNT aortic valve in a subset of patients aged 60 or younger at the time of operation tracked patients over a nearly 25-year period, achieved follow-up of 3,299 valve years and determined that expected valve durability for this population was greater than 17 years.

A new study, results of which were presented at the weekend’s European Society of Hypertension(ESH) meeting in Milan, has cast … continue reading “Belgian Study Rains On Renal Denervation Parade”

J&J Company, Cordis Corporation has received FDA clearance of its latest innovation in guiding catheters: the ADROIT™ 6F Guiding Catheter, which the company says means easier advancement of devices, with its 0.072′ diameter, the largest inner diameter of any guiding catheter in the U.S. .

Angioplasty catheter developer, AngioScore, Inc., has announced the FDA approval of a Pre-Market Approval Supplement (PMAS) labeling change allowing inclusion of a summary of the AGILITY Coronary Bifurcation Trial results in the AngioSculpt® PTCA Scoring Balloon Catheter Instructions for Use (IFU).

Micell’s MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System is a thin-strut stent that features elimination of the coating from the stent in 45-60 days and the complete absorption of the polymer coating within 90 days. Uniquely it provides local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events.